UBS Asset Management: 90th investor to endorse the Access to Medicine Index
Eight new investors have pledged support to the Foundation’s research and signed the Access to Medicine Index Investor Statement since the release of the 2018 Access to Medicine Index last November. UBS Asset Management is the latest (90th) investor, taking the total asset under management (AUM) of all signatory investors to more than USD 11.8 trillion.
The eight new investors - Aequo Shareholder Engagement Services, Alecta, Etica Sgr - Responsible Investments, Groupe MACSF, SEB, UBS Asset Management, United Church Funds, and WHEB Asset Management - have all signed the Investor Statement and committed to using the independent analysis of the Foundation in their investment research to compare how pharmaceutical companies manage risks and seize opportunities related to access to medicine.
How do investors and analysts use our research?
There is increasing recognition that access to medicine is material for the pharmaceutical industry. The Access to Medicine Index is viewed by asset managers, asset owners and analysts as one of the most credible sources of information for assessing how pharmaceutical companies strengthen their licence to operate globally by improving access to medicine.
Investors use the Foundation’s independent analysis of ongoing developments in the pharmaceutical sector to inform their dialogue with companies on important ESG topics such as compliance, governance, pricing, R&D and supply chain management.
Find out more about our work with investors here.
